GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bayer AG (XBUL:BAYN) » Definitions » EBITDA Margin %

Bayer AG (XBUL:BAYN) EBITDA Margin % : 10.59% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bayer AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bayer AG's EBITDA for the three months ended in Sep. 2024 was лв2,191 Mil. Bayer AG's Revenue for the three months ended in Sep. 2024 was лв20,677 Mil. Therefore, Bayer AG's EBITDA margin for the quarter that ended in Sep. 2024 was 10.59%.


Bayer AG EBITDA Margin % Historical Data

The historical data trend for Bayer AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bayer AG EBITDA Margin % Chart

Bayer AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.12 -5.79 14.63 25.68 21.93

Bayer AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.90 18.78 31.62 15.50 10.59

Competitive Comparison of Bayer AG's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Bayer AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bayer AG's EBITDA Margin % falls into.



Bayer AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bayer AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=21290.6/97091.739
=21.93 %

Bayer AG's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=2190.516/20677.139
=10.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bayer AG  (XBUL:BAYN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Bayer AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Bayer AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bayer AG Business Description

Address
Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.